Aquestive Therapeutics vs Nektar Therapeutics
Nektar Therapeutics reported revenue of $55 million in fiscal 2025, 1.2 times Aquestive Therapeutics' $44 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and Nektar Therapeutics' fell 43.9%. Aquestive Therapeutics had an operating margin of -159.5%, against -253.7% at Nektar Therapeutics. Free cash flow was −$53 million at Aquestive Therapeutics and −$209 million at Nektar Therapeutics.
Side by side
| Aquestive Therapeutics | Nektar Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $44M | $55M |
| Revenue growth | −22.6% | −43.9% |
| Revenue growth a year, last 5 years | −0.6% | −18.4% |
| Gross margin | 58.4% | 100.0% |
| Operating margin | −159.5% | −253.7% |
| Net margin | −188.1% | −297.1% |
| Free cash flow | −$53M | −$209M |
| Free cash flow margin | −119.0% | −377.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 23.3% | 23.1% |
| Last close | $3.91 | $37.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $2.4 million |
| Piotroski F-score | 2 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aquestive TherapeuticsNektar Therapeutics
Operating margin
Percent of revenue
Aquestive TherapeuticsNektar Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsNektar Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and Nektar Therapeutics pages.